168 related articles for article (PubMed ID: 35085258)
1. Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells.
Murayama MA; Takada E; Takai K; Arimitsu N; Shimizu J; Suzuki T; Suzuki N
PLoS One; 2022; 17(1):e0260838. PubMed ID: 35085258
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
3. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
4. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
Yang L; Huang F; Mei J; Wang X; Zhang Q; Wang H; Xi M; You Z
Int J Gynecol Cancer; 2017 Feb; 27(2):196-205. PubMed ID: 27870715
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
8. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
[TBL] [Abstract][Full Text] [Related]
9. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in triple-negative breast cancer.
Mittendorf EA; Philips AV; Meric-Bernstam F; Qiao N; Wu Y; Harrington S; Su X; Wang Y; Gonzalez-Angulo AM; Akcakanat A; Chawla A; Curran M; Hwu P; Sharma P; Litton JK; Molldrem JJ; Alatrash G
Cancer Immunol Res; 2014 Apr; 2(4):361-70. PubMed ID: 24764583
[TBL] [Abstract][Full Text] [Related]
11. ERα is a negative regulator of PD-L1 gene transcription in breast cancer.
Liu L; Shen Y; Zhu X; Lv R; Li S; Zhang Z; Shi YG; Tan L
Biochem Biophys Res Commun; 2018 Oct; 505(1):157-161. PubMed ID: 30241942
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is increased in a subset of basal type breast cancer cells.
Soliman H; Khalil F; Antonia S
PLoS One; 2014; 9(2):e88557. PubMed ID: 24551119
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
Front Immunol; 2021; 12():767666. PubMed ID: 34899719
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
Zhao Q; Guo J; Zhao Y; Shen J; Kaboli PJ; Xiang S; Du F; Wu X; Li M; Wan L; Li X; Wen Q; Li J; Zou C; Xiao Z
Epigenomics; 2020 Dec; 12(24):2155-2171. PubMed ID: 33337915
[No Abstract] [Full Text] [Related]
16. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
[TBL] [Abstract][Full Text] [Related]
20. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
